{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:58:17Z","timestamp":1772927897267,"version":"3.50.1"},"reference-count":53,"publisher":"Japan Oil Chemists' Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Oleo Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5650\/jos.ess25089","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T22:13:38Z","timestamp":1772316818000},"page":"331-345","source":"Crossref","is-referenced-by-count":0,"title":["<i>Houttuynia cordata<\/i> Thunb. Essential Oil Inhibits Diffuse Large B-cell lymphoma Growth"],"prefix":"10.5650","volume":"75","author":[{"given":"Youmei","family":"Peng","sequence":"first","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangkun","family":"Liu","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"},{"name":"School of Basic Medical Science, Zhengzhou University, Zhengzhou 450001, CHINA; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Fu","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"},{"name":"School of Basic Medical Science, Zhengzhou University, Zhengzhou 450001, CHINA; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhuan","family":"Li","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinfeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yarong","family":"Wang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Henan Institute for Drug and Medical Device Control, Zhengzhou 450018, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhe","family":"Rong","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Zhengzhou University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuangli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Pharmacology of liver diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, CHINA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3621","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Roschewski, M.; Phelan, J.D.; Wilson, W.H. Molecular classification and treatment of diffuse large B-Cell lymphoma and primary mediastinal B-Cell lymphoma. Cancer J. 26, 195-205 (2020). doi:10.1097\/PPO.0000000000000450","DOI":"10.1097\/PPO.0000000000000450"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Sehn, L.H.; Salles, G. Diffuse large B-Cell lymphoma. N. Engl. J. Med. 384, 842-858 (2021). doi:10.1056\/NEJMra2027612","DOI":"10.1056\/NEJMra2027612"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Musuraca, G.; Fattori, P.P.; Ceccolini, M.; Cangini, D.; Giannini, M.B. et al. Prolonged 18FDG\u2013PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). Am. J. Hematol. 86, 79-80 (2011). doi:10.1002\/ajh.21869","DOI":"10.1002\/ajh.21869"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Roh, J.; Pak, H.-K.; Jeong, S.; Hwang, S.; Kim, D.E. et al. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma. Biochem. Biophys. Res. Commun. 673, 36-43 (2023). doi:10.1016\/j.bbrc.2023.06.061","DOI":"10.1016\/j.bbrc.2023.06.061"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Falduto, A.; Cimino, F.; Speciale, A.; Musolino, C.; Gangemi, S. et al. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Blood Rev. 31, 235-249 (2017). doi:10.1016\/j.blre.2017.02.005.","DOI":"10.1016\/j.blre.2017.02.005"},{"key":"6","unstructured":"6) Stanisavljevic, N.S.; Marisavljevic, D.Z. Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity. J. BUON. 15, 290-296 (2010)."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Lin, C.-H.; Chao, L.K.; Lin, L.-Y.; Wu, C.-S.; Chu, L.-P. et al. Analysis of volatile compounds from different parts of Houttuynia cordata Thunb. Molecules 27, 8893 (2022). doi:10.3390\/molecules27248893","DOI":"10.3390\/molecules27248893"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Kumar, M.; Prasad, S.K.; Hemalatha, S. A current update on the phytopharmacological aspects of Houttuynia cordata Thunb. Pharmacogn. Rev. 8, 22-35 (2014). doi:10.4103\/0973-7847.125525","DOI":"10.4103\/0973-7847.125525"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Shingnaisui, K.; Dey, T.; Manna, P.; Kalita, J. Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review. J. Ethnopharmacol. 220, 35-43 (2018). doi:10.1016\/j.jep.2018.03.038","DOI":"10.1016\/j.jep.2018.03.038"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Chiow, K.H.; Phoon, M.C.; Putti, T.; Tan, B.K.H.; Chow, V.T. Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac. J. Trop. Med. 9, 1-7 (2016). doi:10.1016\/j.apjtm.2015.12.002.","DOI":"10.1016\/j.apjtm.2015.12.002"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) \u0158eb\u00ed\u010dkov\u00e1, K.; Bajer, T.; \u0160ilha, D.; Houdkov\u00e1, M.; Ventura, K.; Bajerov\u00e1, P. Chemical composition and determination of the antibacterial activity of essential oils in liquid and vapor phases extracted from two different southeast Asian herbs\u2013Houttuynia cordata (Saururaceae) and Persicaria odorata (Polygonaceae). Molecules 25, 2432 (2020). doi:10.3390\/molecules25102432","DOI":"10.3390\/molecules25102432"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Sekita, Y.; Murakami, K.; Yumoto, H.; Mizuguchi, H.; Amoh, T. et al. Anti-bacterial and anti-inflammatory effects of ethanol extract from Houttuynia cordata poultice. Biosci. Biotechnol. Biochem. 80, 1205-1213 (2016). doi:10.1080\/09168451.2016.1151339","DOI":"10.1080\/09168451.2016.1151339"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Qi, S.; Zha, L.; Peng, Y.; Luo, W.; Chen, K. et al. Quality and metabolomics analysis of Houttuynia cordata based on HS-SPME\/GC-MS. Molecules 27, 3921 (2022). doi:10.3390\/molecules27123921","DOI":"10.3390\/molecules27123921"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Wu, Y.; Liu, J.; Kang, S.; Dai, Z.; Ma, S. Rapid analysis of aristolochic acids and aristolactams in Houttuyniae Herba by LC-MS\/MS. Molecules 27, 8969 (2022). doi:10.3390\/molecules27248969","DOI":"10.3390\/molecules27248969"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Das, S.K.; Deka, S.J.; Paul, D.; Gupta, D.D. et al. In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes. J. Biomol. Struct. Dyn. 40, 6857-6867 (2022). doi:10.1080\/07391102.2021.1891136","DOI":"10.1080\/07391102.2021.1891136"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Liu, J.; Zhu, X.; Yang, D.; Li, R.; Jiang, J. Effect of heat treatment on the anticancer activity of Houttuynia cordata Thunb aerial stem extract in human gastric cancer SGC-7901 cells. Nutr. Cancer 73, 160-168 (2021). doi:10.1080\/01635581.2020.1737153","DOI":"10.1080\/01635581.2020.1737153"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lou, Y.; Guo, Z.; Zhu, Y.; Kong, M.; Zhang, R. et al. Houttuynia cordata Thunb. and its bioactive compound 2-undecanone significantly suppress benzo(a)pyrene-induced lung tumorigenesis by activating the Nrf2-HO-1\/NQO-1 signaling pathway. J. Exp. Clin. Cancer Res. 38, 242 (2019). doi:10.1186\/s13046-019-1255-3","DOI":"10.1186\/s13046-019-1255-3"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Subhawa, S.; Chewonarin, T.; Banjerdpongchai, R. The effects of Houttuynia cordata Thunb and Piper ribesioides Wall extracts on breast carcinoma cell proliferation, migration, invasion and apoptosis. Molecules 25, 1196 (2020). doi:10.3390\/molecules25051196","DOI":"10.3390\/molecules25051196"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Subhawa, S.; Naiki-Ito, A.; Kato, H.; Naiki, T.; Komura, M. et al. Suppressive effect and molecular mechanism of Houttuynia cordata Thunb. extract against prostate carcinogenesis and castration-resistant prostate cancer. Cancers 13, 3403 (2021). doi:10.3390\/cancers13143403","DOI":"10.3390\/cancers13143403"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Yanarojana, M.; Nararatwanchai, T.; Thairat, S.; Tancharoen, S. Antiproliferative activity and induction of apoptosis in human melanoma cells by Houttuynia cordata Thunb extract. Anticancer Res. 37, 6619-6628 (2017). doi:10.21873\/anticanres.12119.","DOI":"10.21873\/anticanres.12119"},{"key":"21","unstructured":"21) Zhang, Z.; Zhao, N.; Wang, Y.; Zou, M.; Zhao, Z. et al. Effect of volatile oil from Houttuynia cordata Thunb. on proliferation and apoptosis of Raji cells. J. Zhengzhou Univ. (Med. Sci.). 51, 474-477 (2016)."},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Fruman, D.A.; Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156 (2014). doi:10.1038\/nrd4204","DOI":"10.1038\/nrd4204"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656 (2002). doi:10.1038\/nrc883","DOI":"10.1038\/nrc883"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Senichkin, V.V.; Pervushin, N.V.; Zuev, A.P.; Zhivotovsky, B.; Kopeina, G.S. Targeting Bcl-2 family proteins: What, where, when? Biochemistry (Moscow) 85, 1210-1226 (2020). doi:10.1134\/S0006297920100090","DOI":"10.1134\/S0006297920100090"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Kale, J.; Osterlund, E.J.; Andrews, D.W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65-80 (2018). doi:10.1038\/cdd.2017.186","DOI":"10.1038\/cdd.2017.186"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cavalcante, G.C.; Schaan, A.P.; Cabral, G.F.; Santana-da-Silva, M.N.; Pinto, P. et al. A cell's fate: An overview of the molecular biology and genetics of apoptosis. Int. J. Mol. Sci. 20, 4133 (2019). doi:10.3390\/ijms20174133","DOI":"10.3390\/ijms20174133"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Juin, P.; Geneste, O.; Gautier, F.; Depil, S.; Campone, M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer. 13, 455-465 (2013). doi:10.1038\/nrc3538","DOI":"10.1038\/nrc3538"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28) Kapoor, I.; Li, Y.; Sharma, A.; Zhu, H.; Bodo, J. et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 10, 924 (2019). doi:10.1038\/s41419-019-2158-0","DOI":"10.1038\/s41419-019-2158-0"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Wang, J.; Xu-Monette, Z.Y.; Jabbar, K.J.; Shen, Q.; Manyam, G.C. et al. AKT hyperactivation and the potential of AKT-targeted therapy in diffuse large B-cell lymphoma. Am. J. Pathol. 187, 1700-1716 (2017). doi:10.1016\/j.ajpath.2017.04.009.","DOI":"10.1016\/j.ajpath.2017.04.009"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Karmali, R.; Gordon, L.I. Molecular subtyping in diffuse large B cell lymphoma: Closer to an approach of precision therapy. Curr. Treat. Options Oncol. 18, 11 (2017). doi:10.1007\/s11864-017-0449-1","DOI":"10.1007\/s11864-017-0449-1"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31) Rossi, A.; Orecchioni, S.; Falvo, P.; Tabanelli, V.; Baiardi, E. et al. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Leukemia 36, 197-209 (2022). doi:10.1038\/s41375-021-01347-6","DOI":"10.1038\/s41375-021-01347-6"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Xu, W.; Berning, P.; Lenz, G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood 138, 1110-1119 (2021). doi:10.1182\/blood.2020006784","DOI":"10.1182\/blood.2020006784"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33) Morschhauser, F.; Feugier, P.; Flinn, I.W.; Gasiorowski, R.; Greil, R. et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137, 600-609 (2021). doi:10.1182\/blood.2020006578","DOI":"10.1182\/blood.2020006578"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34) Li, G.; Hu, Y.; Li, D.; Zhang, Y.; Guo, H. et al. Vincristine-induced peripheral neuropathy: A mini-review. Neurotoxicology. 81, 161-171 (2020). doi:10.1016\/j.neuro.2020.10.004","DOI":"10.1016\/j.neuro.2020.10.004"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35) Li, T.; Kandula, T.; Cohn, R.J.; Kiernan, M.C.; Park, S.B.; Farrar, M.A. Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia. Clin. Neurophysiol. 154, 157-168 (2023). doi:10.1016\/j.clinph.2023.08.002","DOI":"10.1016\/j.clinph.2023.08.002"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36) Bojarczuk, K.; Wienand, K.; Ryan, J.A.; Chen, L.; Villalobos-Ortiz, M. et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood 133, 70-80 (2019). doi:10.1182\/blood-2018-08-872465","DOI":"10.1182\/blood-2018-08-872465"},{"key":"37","unstructured":"37) Xiaohua, L.; Zhihang, D.; Jianjun, Y.; Yongyu, Z.; Yihang, L. et al. Bornyl acetate extracted from Sharen (Fructus amomi) inhibits proliferation, invasion and induces apoptosis by suppressing phosphatidylinositol-3-kinase\/protein kinase B signaling in colorectal cancer. J. Tradit. Chin. Med. 43,1081-1091 (2023). doi: 10.19852\/j.cnki.jtcm.20231018.002"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38) Fidyt, K.; Fiedorowicz, A.; Strz\u0105da\u0142a, L.; Szumny, A. \u0392-Caryophyllene and \u0392-caryophyllene oxide\u2013Natural compounds of anticancer and analgesic properties. Cancer Med. 5, 3007-3017 (2016). doi:10.1002\/cam4.816","DOI":"10.1002\/cam4.816"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39) An, Z.; Feng, X.; Sun, M.; Wang, Y.; Wang, H.; Gong, Y. Chamomile essential oil: Chemical constituents and antitumor activity in MDA-MB-231 cells through PI3K\/Akt\/mTOR signaling pathway. Chem. Biodivers. 20, e202200523 (2023). doi:10.1002\/cbdv.202200523","DOI":"10.1002\/cbdv.202200523"},{"key":"40","unstructured":"40) Hata, T.; Sakaguchi, I.; Mori, M.; Ikeda, N.; Kato, Y. et al. Induction of apoptosis by Citrus paradisi essential oil in human leukemic (HL-60) cells. In Vivo 17, 553-559 (2003)."},{"key":"41","doi-asserted-by":"publisher","unstructured":"41) Jin, J.-S.; Chou, J.M.; Tsai, W.-C.; Chen, Y.-C.; Chen, Y. et al. Effectively \u03b1-terpineol suppresses glioblastoma aggressive behavior and downregulates KDELC2 expression. Phytomedicine 127, 155471 (2024). doi:10.1016\/j.phymed.2024.155471","DOI":"10.1016\/j.phymed.2024.155471"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42) Kim, J.; Jung, K.H.; Choi, J.G.; Oh, M.S.; Hong, S.-S. Artemisiae Iwayomogii Herba inhibits growth, motility, and the PI3K\/AKT\/mTOR signaling pathway in hepatocellular carcinoma cells. Planta Med. 86, 717-727 (2020). doi:10.1055\/a-1167-4284","DOI":"10.1055\/a-1167-4284"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43) Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629-661 (2016). doi:10.1021\/acs.jnatprod.5b01055","DOI":"10.1021\/acs.jnatprod.5b01055"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44) Ma, Q.; Wei, R.; Wang, Z.; Liu, W.; Sang, Z. et al. Bioactive alkaloids from the aerial parts of Houttuynia cordata. J. Ethnopharmacol. 195, 166-172 (2017). doi:10.1016\/j.jep.2016.11.013","DOI":"10.1016\/j.jep.2016.11.013"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45) Wu, Z.; Deng, X.; Hu, Q.; Xiao, X.; Jiang, J. et al. Houttuynia cordata Thunb: An ethnopharmacological review. Front. Pharmacol. 12, 714694 (2021). doi:10.3389\/fphar.2021.714694","DOI":"10.3389\/fphar.2021.714694"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46) Chang, J.-S.; Chiang, L.-C.; Chen, C.-C.; Liu, L.-T.; Wang, K.-C.; Lin, C.-C. Antileukemic activity of Bidens pilosa L. var. minor (Blume) Sherff and Houttuynia cordata Thunb. Am. J. Chin. Med. 29, 303-312 (2001). doi:10.1142\/S0192415X01000320","DOI":"10.1142\/S0192415X01000320"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47) Prommaban, A.; Kodchakorn, K.; Kongtawelert, P.; Banjerdpongchai, R. Houttuynia cordata Thunb fraction induces human leukemic Molt-4 cell apoptosis through the endoplasmic reticulum stress pathway. Asian Pac. J. Cancer Prev. 13, 1977-1981 (2012). doi:10.7314\/APJCP.2012.13.5.1977","DOI":"10.7314\/APJCP.2012.13.5.1977"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48) Kumnerdkhonkaen, P.; Saenglee, S.; Asgar, M.A.; Senawong, G.; Khongsukwiwat, K.; Senawong, T. Antiproliferative activities and phenolic acid content of water and ethanolic extracts of the powdered formula of Houttuynia cordata Thunb. fermented broth and Phyllanthus emblica Linn. fruit. BMC Complement. Altern. Med. 18, 130 (2018). doi:10.1186\/s12906-018-2185-x","DOI":"10.1186\/s12906-018-2185-x"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49) Zhang, X.; Liu, Y. Targeting the PI3K\/AKT\/mTOR signaling pathway in primary central nervous system lymphoma: Current status and future prospects. CNS Neurol. Disord. Drug Targets. 19, 165-173 (2020). doi:10.2174\/1871527319666200517112252","DOI":"10.2174\/1871527319666200517112252"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50) Yuan, T.; Zhang, F.; Zhou, X.; Li, Y.; Zhang, Y. et al. Inhibition of the PI3K\/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. Oncol. Lett. 17, 2553-2560 (2019). doi:10.3892\/ol.2019.10029","DOI":"10.3892\/ol.2019.10029"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51) Lenz, G.; Hawkes, E.; Verhoef, G.; Haioun, C.; Lim, S.T. et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 34, 2184-2197 (2020). doi:10.1038\/s41375-020-0743-y","DOI":"10.1038\/s41375-020-0743-y"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52) Stewart, C.M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C. et al. Phase I\/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring. Clin. Cancer Res. 28, 45-56 (2022). doi:10.1158\/1078-0432.CCR-21-2183","DOI":"10.1158\/1078-0432.CCR-21-2183"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53) Tannoury, M.; Garnier, D.; Susin, S.A.; Bauvois, B. Current status of novel agents for the treatment of B cell malignancies: What's coming next? Cancers. 14, 6026 (2022). doi:10.3390\/cancers14246026","DOI":"10.3390\/cancers14246026"}],"container-title":["Journal of Oleo Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jos\/75\/3\/75_jos.ess25089\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:17:16Z","timestamp":1772857036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jos\/75\/3\/75_jos.ess25089\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5650\/jos.ess25089","relation":{},"ISSN":["1345-8957","1347-3352"],"issn-type":[{"value":"1345-8957","type":"print"},{"value":"1347-3352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"jos.ess25089"}}